CAMKK2 and fatty liver disease: These findings support the notion that CaMKK2 controls metabolic flexibility in the liver and are further supported by our observations here that STO-609S treatment in two mouse models of NAFLD promotes reprogramming of glycolytic and fatty acid oxidation programs to reverse hepatic steatosis.